Donate Toggle Menu

In the phase III CheckMate-9ER trial, nivolumab (Opdivo) plus cabozantinib (Cabometyx) combined improved overall survival (OS) and progression-free survival (PFS) compared with sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC) who had not previously received treatment.

“The results from the pivotal CheckMate -9ER trial clearly demonstrate the combination of cabozantinib plus nivolumab provides a clinically meaningful benefit in the key efficacy measures of progression-free survival and overall survival for previously untreated kidney cancer patients,” said Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School.

“Preliminary assessment of the data shows the combination of a 40mg dose of cabozantinib plus nivolumab demonstrated a favorable safety profile. If approved, this combination may become an important new first-line option for patients with metastatic renal cell carcinoma. We look forward to presenting detailed results at an upcoming congress.”

Read more about this trial at OncLive and at Bristol Myers Squibb.

2 thoughts on “Opdivo plus Cabometyx improved overall survival in people with RCC in a phase III trial”

  1. I’m RCC patient for 8 years. I start my treatment with Sutent. Now I use Opdivo for a year. My life with Opdivo change. I have better quality life.

    1. I also started with Sutent and now I am on Opdivo and have been for 39 treatments. My last PET scan came back showing no cancer but my doc says to stay on a maintenance program of one infusion a month or it will come back. Renal cell cancer does not go away but it hides and becomes small enough as to not show on scans. This is good news knowing the cancer is not eating away at by body. Opdivo in really so much better than Sutent as far as side effects. Good to hear you are doing better and keep it up because it does work as long as your body can handle it.

Leave a Reply

Your email address will not be published. Required fields are marked *